DBV Technologies SA – American (DBVT) Gets a Buy Rating from JMP Securities

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on DBV Technologies SA – American (DBVTResearch Report) today and set a price target of $5.00. The company’s shares closed last Monday at $2.51.

According to, Wolleben has 0 stars on 0-5 stars ranking scale with an average return of -9.6% and a 35.1% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Madrigal Pharmaceuticals, and Clearside Biomedical.

Currently, the analyst consensus on DBV Technologies SA – American is a Moderate Buy with an average price target of $5.50.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $5.99 and a one-year low of $1.15. Currently, DBV Technologies SA – American has an average volume of 778.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Read More on DBVT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More